Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-01
2007-05-01
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S093000
Reexamination Certificate
active
09447218
ABSTRACT:
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
REFERENCES:
patent: 3326924 (1967-06-01), Villani
patent: 3391143 (1968-07-01), Kaiser et al.
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3940485 (1976-02-01), Levinson et al.
patent: 4282233 (1981-08-01), Vilani
patent: 4371516 (1983-02-01), Gregory et al.
patent: 4659716 (1987-04-01), Villani et al.
patent: 4777170 (1988-10-01), Heinrich
patent: 4990535 (1991-02-01), Cho et al.
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5100675 (1992-03-01), Cho et al.
patent: 5314697 (1994-05-01), Kwan et al.
patent: 5595997 (1997-01-01), Aberg et al.
patent: 5714501 (1998-02-01), Timmerman et al.
patent: 5731319 (1998-03-01), Aberg et al.
patent: 5900421 (1999-05-01), Handley et al.
patent: 0 288 640 (1988-11-01), None
patent: 396404 (1990-11-01), None
patent: 0780127 (1997-06-01), None
patent: W O 85/03707 (1985-08-01), None
patent: WO 85/03707 (1985-08-01), None
patent: WO85/03707 (1985-08-01), None
patent: WO 92/00293 (1992-01-01), None
patent: WO 92/11034 (1992-07-01), None
patent: WO 92/20377 (1992-11-01), None
patent: WO 96/20708 (1996-07-01), None
patent: WO 97/28797 (1997-08-01), None
patent: WO 99/32125 (1999-07-01), None
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy, 16th Edition, Merck Research Laboratories, Rahway, NJ, May 1992, only pp. 332-334 supplied.
Gennaro et al. (eds.),Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co., Easton, PA, 1990, only pp. 678 and 1123-1124 (from Chs. 34 & 59, respectively) are supplied.
Thomas et al. (eds.),Taber's Cyclopedic Medical Dictionary, 17th Illustrated Edition, F. A. Davis Company, Philadelphia, PA, 1993, only pp. 2091-2092 supplied.
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy, 16th Edition, Merck Research Laboratories, Rahway, NJ, May 1992, only pp. 332-334 supplied.
Gennaro et al. (eds.),Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co., Easton, PA, 1990, only pp. 678 and 1123-1124 (from Chs. 34 & 59, respectively) are supplied.
Thomas et al. (eds.),Taber's Cyclopedic Medical Dictionary, 17th Illustrated Edition, F. A. Davis Company, Philadelphia, PA, 1993, only pp. 2091-2092 supplied.
Bocian, R, “Hay Fever (Allergic Rhinitis): Current Management Approaches,” Palo Alto Medical Foundation, Spring, 2000, see <http://www.pamf.org/health/toyourhealth/hayfever/html>.
E. W. Monroe, “Loratadine in the Treatment of Urticaria,”Clinical Therapeutics, 19(2), 232-242 (1997).††
Knowles et al., “Astemizole and terfenadine-Induces Cardiovascular Effects,”Canadian Journal of Hospital Pharmacy, 45(1), 33 & 37 (Feb. 1992).††
Isselbacher et al.†† (eds.),Harrison's Principles of Internal Medicine, Thirteenth Edition, McGraw-Hill, Inc., New York, NY, 1994, only pp. 402-403 supplied.
Estelle et al.††, “The Pharmacology and Use of H1-Receptor-Antagonist Drugs,”The New England Journal of Medicine, 330(23), 1665-1670 (Jun. 9, 1994).
Berkow et al.†† (eds.),The Merck Manual of Diagnosis and Therapy, Sixteenth Edition, Merck & Co., Rahway, NJ, May 1992, only pp. 1262-1265 provided.
Brandes et al.††, “Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H1-Antihistamines: Predictivein vitroCorrelates,”PubMed(National Library of Medicine USA): PMID 7909571, published on line in 1994: only Abstract supplied.
E. A. Swinyard (I), “Gastrointestinal Drugs,” Chapter 39 inRemington's Pharmaceutical Sciences, 18th Edition, Gennaro et al. (eds.), Mack Publishing Co., Easton, PA, 1990, only pp. 774-799 supplied.
E. A. Swinyard (II), “Histamine and Antihistamines,” Chapter 59 inRemington's Pharmaceutical Sciences, 18th Edition, Gennaro et al. (eds.), Mack Publishing Co., Easton, PA, 1990, only pp. 1123-1131 supplied.
Berkow et al. (eds.), The Merck Manual of Diagnosis and Therapy, 16th Edition, Merck Research Laboratories, Rahway, NJ, May 1992, only pp. 332-334 supplied.
Gennaro et al. (eds.), Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co., Easton, PA, 1990, only pp. 678 and 1123-1124 (from Chs. 34 & 59, respectively) are supplied.
Thomas et al. (eds.), Taber's Cyclopedic Medical Dictionary, 17th Illustrated Edition, F. A. Davis Company, Philadelphia, PA, 1993 only pp. 2091-2092 supplied.
Bocian, R, “Hay Fever (Allergic Rhinitis): Current Management Approaches,” Palo Alto Medical Foundation, Spring, 2000, see <http://www.pamf.org/health/toyourhealth/hayfever/html>.
E. W. Monroe, “Loratadine in the Treatment of Urticaria,” Clinical Therapeutics, 19(2), 232-242 (1997).
Knowles et al., “Astemizole and Terfenadine-Induces Cardiovascular Effects,” Canadian Journal of Hospital Pharmacy, 45(1), 33 &37 (Feb. 1992).
Isselbacher et al. (eds.), HarrisonÖs Principles of Internal Medicine, Thirteenth Edition, McGraw-Hill, Inc., New York, NY, 1994, only pp. 402-403 supplied.
Estelle et al. , “The Pharmacology and Use of H1-Receptor-Antagonist Drugs,” The New England Journal of Medicine, 330(23), 1665-1670 (Jun. 9, 1994).
Berkow et al. (eds.), The Merck Manual of Diagnosis and Therapy, Sixteenth Edition, Merck & Co., Rahway, NJ, May 1992, only pp. 1262-1265 provided.
Brandes et al. , “Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H1-Antihistamines; Predictive in vitro Correlates” PubMed (National Library of Medicine USA): PMID 7909571, published on line in 1994: only Abstract.
E. A. Swinyard (I), “Gastrointestinal Drugs,” Chapter 39 in Remington's Pharmaceutical Sciences, 18th Edition, Gennaro et al. (eds.), Mack Publishing Co., Easton, PA, 1990, only pp. 774-799 supplied).
E. A. Swinyard (II), “Histamine and Antihistamines,” Chapter 59 in Remington's Pharmaceutical Sciences, 18th Edition, Gennaro et al. (eds.), Mack Publishing Co., Easton, PA, 1990, only pp. 1123-1131 supplied.
Brandes et al. (II), “Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H1-Antihistamines: Predictive in vitro Correlates,” Journal of the National Cancer Institute, 86(10), 770-775 (May 18, 1994).
S. L. Nightingale, “Warning Issued on Nonsedating Antihistamines Terfenadine and Astemizole,” Journal of the American Medical Association, 268(6), 705 (Aug. 12, 1992).
Berthon et al., “In Vitro Inhibition by Loratadine and Descarbethoxy-Ioratadine, of Histamine Release from Human Basophils, and . . . (RBL-2H3),” Biochemical Pharmacology, 47(5), 789-794 (1994).
J. F. Wiley II, et al., “Cardiotoxic Effects of Astemizole Overdose in Children,” Journal of Pediatrics, 120(5), 799-802 (May 1992).
A. Van Peer et al., “Keloconazole Inhibits Loratadine Metabolism in Man,” European Journal of Allergy & Clinical Immunology, 48(Suppl. 16), 34, 1993: Derwent Abstract Accessio No.: 93-55671; only abstract supplied.
C. I. Ezeamuzie et al., “Effect of Histamine H2-Receptor Antagonists on Acute Inflammatory of the Rat Paw Oedema,” J. Pharm. Pharmacol., 41, 261-265 (1989).
K. Kyuki et al., “Topical Anti-Inflammatory Activity of Dexamethasone 17-Valerate,” Nippon Yakurigaku Zasshi 77(1), 73-85 (Jan. 1981); Pub Med Abstract/Translation from Japanese, PMID 7262708; only Abstract supplied.
S. Kawaguchi et al., “Nasal Mast Cell in Experimentally Induced Allergic Rhinitis in Guinea-Pigs,” Clinical and Experimental Allergy, 24, 238-244 (1994).
T. Abe et al., “Antiallergic Effects of ZCR-2060: Effect on Allergic Cutaneous Reactions and Rhinitis Models
Aberg A. K. Gunnar
McCullough John R.
Smith Emil R.
Chang Celia
Jones Day
Sepracor Inc.
LandOfFree
Methods for treating urticaria using descarboethoxyloratadine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating urticaria using descarboethoxyloratadine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating urticaria using descarboethoxyloratadine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3720821